VXL — Vaxil Bio Balance Sheet
0.000.00%
Last trade - 00:00
- CA$2.05m
- CA$1.05m
- 34
- 20
- 40
- 22
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.753 | 0.083 | 1.51 | 2.24 | 1.51 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.075 | 0.027 | 0.124 | 0.035 | 0.02 |
Prepaid Expenses | |||||
Total Current Assets | 0.828 | 0.11 | 1.63 | 2.28 | 1.54 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.062 | 0.095 | 0.027 | 0.002 | 0 |
Total Assets | 0.89 | 0.205 | 1.66 | 2.29 | 1.54 |
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.455 | 0.777 | 0.857 | 0.585 | 0.405 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.455 | 0.788 | 0.857 | 0.585 | 0.405 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 0.435 | -0.583 | 0.804 | 1.7 | 1.14 |
Total Liabilities & Shareholders' Equity | 0.89 | 0.205 | 1.66 | 2.29 | 1.54 |
Total Common Shares Outstanding |